Pfizer (PFE)

Company Profile

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.

Company profile

Ticker

PFE

Exchange

NYSE

Website

www.pfizer.com/

CEO

Albert Bourla

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene • Royalty Pharma ...

SEC CIK

0000078003

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

356 Royalty Inc. • Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharma IE Limited • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, LLC • Arena Pharmaceuticals Development GmbH ...

PFE stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$43.33

Low target

$38.00

High target

$50.00

Latest filings (excl ownership)

View all

9 Aug 23

Pfizer Reports Second-Quarter 2023 Results

1 Aug 23

8-K

Departure of Directors or Certain Officers

Prospectus supplement for primary offering

18 May 23

FWP

Free writing prospectus

16 May 23

424B3

Prospectus supplement

15 May 23

POSASR

Automatic shelf registration (post-effective amendment)

10 May 23

Transcripts

View all

PFE

Earnings call transcript

2023 Q2

1 Aug 23

PFE

Earnings call transcript

2023 Q1

2 May 23

PFE

Earnings call transcript

2022 Q4

31 Jan 23

PFE

Earnings call transcript

2022 Q3

1 Nov 22

PFE

Earnings call transcript

2022 Q2

28 Jul 22

PFE

Earnings call transcript

2022 Q1

3 May 22

PFE

Earnings call transcript

2021 Q4

8 Feb 22

PFE

Earnings call transcript

2021 Q3

3 Nov 21

PFE

Earnings call transcript

2021 Q2

29 Jul 21

PFE

Earnings call transcript

2021 Q1

4 May 21

Latest ownership filings

View all

Financial summary

Financial statements Chart PFE financial data

Quarter (USD)	Jul 23	Apr 23	Dec 22	Oct 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.70 bn	2.70 bn	2.70 bn	2.70 bn	2.70 bn	2.70 bn
Cash burn (monthly)	(no burn)	(no burn)	(no burn)	(no burn)	402.67 mm	(no burn)
Cash used (since last report)	n/a	n/a	n/a	n/a	1.25 bn	n/a
Cash remaining	n/a	n/a	n/a	n/a	1.45 bn	n/a
Runway (months of cash)	n/a	n/a	n/a	n/a	3.6	n/a

Beta Read what these cash burn values mean

Financial data from Pfizer earnings reports.

Institutional ownership, Q2 2023

PFE institutional ownership history Ownership history

67.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2883	3021	-4.6%
Opened positions	137	131	+4.6%
Closed positions	275	300	-8.3%
Increased positions	1289	1332	-3.2%
Reduced positions	1196	1276	-6.3%

13F shares	Current	Prev Q	Change
Total value	141.40 tn	157.53 tn	-10.2%
Total shares	3.82 bn	3.83 bn	-0.2%
Total puts	53.12 mm	40.82 mm	+30.1%
Total calls	37.45 mm	27.49 mm	+36.3%
Total put/call ratio	1.4	1.5	-4.5%

Largest owners	Shares	Value	Change
Vanguard	508.09 mm	$18.64 tn	-0.1%
BLK Blackrock	445.15 mm	$16.33 tn	-0.1%
STT State Street	287.20 mm	$10.53 tn	+1.9%
Wellington Management	233.11 mm	$8.55 tn	+6.5%
Capital World Investors	199.01 mm	$7.30 tn	-14.0%
Geode Capital Management	112.87 mm	$4.13 tn	+2.7%
Charles Schwab Investment Management	86.38 mm	$3.15 tn	+3.0%
MS Morgan Stanley	84.58 mm	$3.10 tn	+4.9%
NTRS Northern Trust	63.08 mm	$2.31 tn	-4.7%
BAC Bank Of America	59.62 mm	$2.19 tn	-8.0%

Largest transactions	Shares	Bought/sold	Change
Capital World Investors	199.01 mm	-32.50 mm	-14.0%
Capital International Investors	28.64 mm	-27.36 mm	-48.9%
BMO Bank of Montreal	14.42 mm	+14.42 mm	NEW
Wellington Management	233.11 mm	+14.18 mm	+6.5%
First Trust Advisors	19.49 mm	+8.96 mm	+85.1%
Nordea Investment Management Ab	0.00	-8.28 mm	EXIT
JPM JPMorgan Chase & Co.	42.98 mm	+7.25 mm	+20.3%
National Bank of Canada	8.21 mm	+6.68 mm	+436.2%
BCS Barclays	13.03 mm	+6.47 mm	+98.6%
BNP Paribas Arbitrage	9.75 mm	+5.55 mm	+132.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PFE insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
29 Sep 23	Rady A Johnson	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	33.17	5	165.85	8,139
29 Sep 23	Jennifer B. Damico	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	33.17	41	1.36 k	22,681
29 Sep 23	Albert Bourla	Phantom Stock Units SSP Common Stock	Grant	Acquire A	No	No	33.17	16	530.72	180,995
29 Sep 23	Smith James C	Phantom Stock Units Common Stock	Grant	Acquire A	No	No	33.17	1,356.648	45.00 k	113,814.136
29 Sep 23	James Quincey	Phantom Stock Units Common Stock	Grant	Acquire A	No	No	33.17	1,168.224	38.75 k	36,520.066